Park Young Gun, Kim Jae Ryun, Kang Seungbum, Seifert Eric, Theisen-Kunde Dirk, Brinkmann Ralf, Roh Young-Jung
Department of Ophthalmology and Visual Science, Catholic University of Korea, Seoul, Republic of Korea.
Medical Laser Center Lübeck GmbH, Lübeck, Germany.
Graefes Arch Clin Exp Ophthalmol. 2016 Sep;254(9):1703-13. doi: 10.1007/s00417-015-3262-1. Epub 2016 Jan 23.
Selective retina therapy (SRT) stimulates retinal pigment epithelium (RPE) cell migration and proliferation into irradiated areas. The objective of this study was to evaluate the efficacy and safety of SRT in Korean patients with clinically significant diabetic macular edema (DME).
Prospective non-randomized interventional case series study. Twenty-three eyes of 21 patients with clinically significant DME were treated with SRT and followed for 6 months. Patients underwent an evaluation of best corrected visual acuity (BCVA) in Early Treatment Diabetic Retinopathy Study (ETDRS) letters. Microperimetry was employed to measure macular sensitivity within the central 10° field, and the central macular thickness (CMT) and maximum macular thickness (MMT) were measured.
An improvement in BCVA of one to two ETDRS lines was observed in 41.2 % of patients and an improvement of greater than two lines in 29.4 %. Although there was no significant change in CMT (P > 0.05), MMT decreased from 465.8 ± 87.4 μm to 434.3 ± 83.9 μm (P = 0.006), and mean macular sensitivity increased from 20.8 ± 3.4dB to 22.5 ± 3.5dB (P = 0.02).
The gains in BCVA and improvement in macular sensitivity demonstrated that SRT may be used as an effective and safe treatment modality in Korean patients with clinically significant DME.
选择性视网膜治疗（SRT）可刺激视网膜色素上皮（RPE）细胞迁移并增殖至受照射区域。本研究的目的是评估SRT对韩国临床显著性糖尿病黄斑水肿（DME）患者的疗效和安全性。
前瞻性非随机干预性病例系列研究。对21例临床显著性DME患者的23只眼进行SRT治疗，并随访6个月。患者接受早期糖尿病视网膜病变研究（ETDRS）字母表最佳矫正视力（BCVA）评估。采用微视野计测量中央10°视野内的黄斑敏感度，并测量中央黄斑厚度（CMT）和最大黄斑厚度（MMT）。
41.2%的患者BCVA提高了1至2行ETDRS视力，29.4%的患者提高超过2行。尽管CMT无显著变化（P>0.05），但MMT从465.8±87.4μm降至434.3±83.9μm（P=0.006），黄斑平均敏感度从20.8±3.4dB提高到22.5±3.5dB（P=0.02）。
BCVA的提高和黄斑敏感度的改善表明，SRT可作为韩国临床显著性DME患者一种有效且安全的治疗方式。
